Allergic rhinitis, which is commonly known as hay fever, is an allergic response to specific allergens. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen, such as pollen, mold, dust, etc., the body release a chemical known as histamine, which defends the body from the allergen. This chemical causes allergy symptoms or allergic rhinitis. Pollen is the most common allergen in seasonal allergic rhinitis. Common symptoms of allergic rhinitis are sneezing, runny nose, stuffy nose, watery eyes, headaches, hives, excessive fatigue, skin rashes, etc..

View Report: https://www.transparencymarketresearch.com/allergic-rhinitis-drugs-market.html

Higher prevalence and incidence of allergic rhinitis among people is expected to drive the allergic rhinitis drugs market during the forecast period. According to a report of the World Allergy Organization, in 2015, around 400 million people suffered from allergic rhinitis across the globe. The introduction of new drugs and nasal sprays for allergic rhinitis is expected to drive the allergy rhinitis drugs market. However, the availability of generic drugs and side effects of allergy rhinitis drugs, such as dry mouth, drowsiness, constipation, agitation, urinary retention, etc., are anticipated to hamper the market in the coming years.

Based on drug class, the global allergic rhinitis drugs market can be classified into oral antihistamines, intranasal corticosteroids, immunotherapies, intranasal antihistamines, and other allergic rhinitis drugs. The oral antihistamines segment is projected to account for a significant share of the market in the near future, as oral antihistamines effectively work to treat allergic rhinitis symptoms with their longer duration of action. Moreover, the new generation of oral antihistamines are less likely to cause side effects. In terms of disease, the allergic rhinitis drugs market can be segmented into seasonal allergic rhinitis, perennial allergic rhinitis, and occupational rhinitis.

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=51384

The perennial allergic rhinitis segment is expected to expand during the forecast period because the symptoms of allergic rhinitis are present throughout the year. Based on route of administration, the market can be categorized into oral and nasal. The oral segment is expected to expand in the coming years, as the oral route of administration is convenient and makes the drugs more bioavailable. In terms of distribution channel, the allergic rhinitis drugs market can be categorized into hospital pharmacies, retail pharmacies, and others. The retail pharmacies segment is expected to constitute a considerable share of the market during the forecast period. This is because nowadays many brands of antihistamines are available over the counter, and patients can buy them easily without a doctor’s prescription. Patients prefer to visit retail pharmacies and buy drugs from retail pharmacies for their convenience.

In terms of region, the global allergic rhinitis drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market. The region is projected to account for a significant share of the global allergic rhinitis drugs market during the forecast period due to high incidence of allergic rhinitis in countries such as the U.S. and Canada. According to the American College of Allergy, Asthma, & Immunology, every year, 40 to 60 million people are effected by allergic rhinitis in North America. According to the European Academy of Allergy and Clinical Immunology, in 2016, more than 150 million people were effected by chronic allergic diseases in Europe. By 2025, the affected population is expected to more than double. An increase in the affected population in Europe is creating demand for drugs to treat allergic rhinitis. This is anticipated to drive the allergic rhinitis drug market in Europe. Rise in the prevalence of allergic rhinitis and launch of new drugs to treat the condition are estimated to propel the allergic rhinitis drugs market in Asia Pacific.

Request TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=51384

Major players operating in the global allergic rhinitis drugs market include GlaxoSmithKline, Merck & Co., Sanofi, Johnson & Johnson, Dr. Reddy’s Laboratories, Allergy Therapeutics, Mylan NV, Sun Pharmaceuticals, Pfizer Inc., and Stallergenes Greer.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us

Transparency Market Research

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com